{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:39:47Z","timestamp":1761892787406},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1007\/s11883-003-0084-0","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T01:09:52Z","timestamp":1180055392000},"page":"124-130","source":"Crossref","is-referenced-by-count":9,"title":["The renin-angiotensin-aldosterone system as a target in coronary disease"],"prefix":"10.1007","volume":"5","author":[{"given":"James H.","family":"O\u2019Keefe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared T.","family":"Lurk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra C.","family":"Kahatapitiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet A.","family":"Haskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"84_CR1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0895-7061(02)02987-4","volume":"15","author":"J Staessen","year":"2002","unstructured":"Staessen J, Thijs L, O\u2019Brien E, et al.: Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002, 15: 835.","journal-title":"Am J Hypertens"},{"key":"84_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004872-200101000-00011","volume":"19","author":"A Zanchetti","year":"2001","unstructured":"Zanchetti A, Crepaldi G, Bond MG, et al.: Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens 2001, 19: 79\u201388.","journal-title":"J Hypertens"},{"key":"84_CR3","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(01)01538-7","volume":"87","author":"HR Brunner","year":"2001","unstructured":"Brunner HR: Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001, 87: 3C-9C.","journal-title":"Am J Cardiol"},{"key":"84_CR4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S, Duquaine D, King S, et al.: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105: 2212\u20132216.","journal-title":"Circulation"},{"key":"84_CR5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3317\/jraas.2001.033","volume":"2","author":"AD Struthers","year":"2001","unstructured":"Struthers AD: Adosterone-induced vasculopathy: a new reversible cause of cardiac death. J Renin Angiotensin Aldosterone Syst 2001, 2: 211\u2013214.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"84_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","volume":"360","author":"S Yusuf","year":"2002","unstructured":"Yusuf S: Two decades of progress in preventing vascular disease. Lancet 2002, 360: 2\u20133.","journal-title":"Lancet"},{"key":"84_CR7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","volume":"287","author":"ES Ford","year":"2002","unstructured":"Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA 2002, 287: 356\u2013359.","journal-title":"JAMA"},{"key":"84_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(00)01044-5","volume":"37","author":"JH O\u2019Keefe","year":"2001","unstructured":"O\u2019Keefe JH, Wetzel M, Moe RR, et al.: Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 2001, 37: 1\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"84_CR9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.HYP.15.6.861","volume":"15","author":"AP Rocchini","year":"1990","unstructured":"Rocchini AP, Moorehead C, DeRemer S, et al.: Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension 1990, 15: 861\u2013866.","journal-title":"Hypertension"},{"key":"84_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145\u2013153.","journal-title":"N Engl J Med"},{"key":"84_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"MICRO-HOPE Study","year":"2000","unstructured":"MICRO-HOPE Study: Effects of ramipril on cardiovascular and micro-vascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE substudy. Lancet 2000, 355: 253\u2013259.","journal-title":"Lancet"},{"key":"84_CR12","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","volume":"286","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Gerstein H, Hoogwerf B, et al., for the HOPE Study Investigators: Ramipril and the development of diabetes. JAMA 2001, 286: 1882\u20131885.","journal-title":"JAMA"},{"key":"84_CR13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, et al., for the CAPtopril Prevention Project (CAPPP) Study Group: Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the CAPtopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353: 611\u2013616.","journal-title":"Lancet"},{"key":"84_CR14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0735-1097(99)00634-8","volume":"35","author":"L Kjoller-Hansen","year":"2000","unstructured":"Kjoller-Hansen L, Steffensen R, Grande P: The Angiotensin-converting enzyme inhibition Post REvascularization Study (APRES). J Am Coll Cardiol 2000, 35: 881\u2013888.","journal-title":"J Am Coll Cardiol"},{"key":"84_CR15","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1161\/01.CIR.99.1.111","volume":"99","author":"A Rivard","year":"1999","unstructured":"Rivard A, Magner M: Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999, 99: 3043\u20133049.","journal-title":"Circulation"},{"key":"84_CR16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.CIR.103.7.919","volume":"103","author":"EM Lonn","year":"2001","unstructured":"Lonn EM, Yusuf S, Dzavik V, et al.: Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation 2001, 103: 919\u2013925.","journal-title":"Circulation"},{"key":"84_CR17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","volume":"102","author":"KK Teo","year":"2000","unstructured":"Teo KK, Burton JR, Buller CE, et al.: Long term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin\/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000, 102: 1748\u20131754.","journal-title":"Circulation"},{"key":"84_CR18","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","volume":"87","author":"B Pitt","year":"2001","unstructured":"Pitt B, O\u2019Neill B, Feldman R, et al.: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001, 87: 1058\u20131063.","journal-title":"Am J Cardiol"},{"key":"84_CR19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359: 995\u20131003.","journal-title":"Lancet"},{"key":"84_CR20","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jama.288.12.1491","volume":"288","author":"E Sverre","year":"2002","unstructured":"Sverre E, Kjeldsen SE, Bj\u00f6rn Dahl\u00f6f B, et al., for the LIFE Study Group: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002, 288: 1491\u20131498.","journal-title":"JAMA"},{"key":"84_CR21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.CIR.0000028099.24188.C4","volume":"106","author":"LH Opie","year":"2002","unstructured":"Opie LH, Parving HH: Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? Circulation 2002, 106: 643\u2013645.","journal-title":"Circulation"},{"key":"84_CR22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, De Seeuw D, et al., for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861\u2013869.","journal-title":"N Engl J Med"},{"key":"84_CR23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-agiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321: 1440\u20131444.","journal-title":"BMJ"},{"key":"84_CR24","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285: 2719\u20132728.","journal-title":"JAMA"},{"key":"84_CR25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM, for the MARVAL Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure independent effect. Circulation 2002, 106: 672\u2013678.","journal-title":"Circulation"},{"key":"84_CR26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"Members of the PROGRESS Collaborative Group","year":"2001","unstructured":"Members of the PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358: 1033\u20131041.","journal-title":"Lancet"},{"key":"84_CR27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on mortality and morbidity in patients with severe heart failure. N Engl J Med 1999, 341: 709\u2013717.","journal-title":"N Engl J Med"},{"key":"84_CR28","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1345\/aph.1C027","volume":"36","author":"AJ Zillich","year":"2002","unstructured":"Zillich AJ, Carter BL: Eplerenone-a novel selective aldosterone blocker. Ann Pharmacother 2002, 36: 1567\u20131576.","journal-title":"Ann Pharmacother"},{"key":"84_CR29","unstructured":"Pitt B: Eplerenone, enalapril and eplerenone\/enalapril combination therapy in patients with left ventricular hypertrophy: 4E trial. Poster presentation at the American College of Cardiology 51st Annual Scientific Session."},{"key":"84_CR30","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","volume":"360","author":"KK Teo","year":"2002","unstructured":"Teo KK, Yusuf S, Pfeffer M, et al.: Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002, 360: 1037\u20131043.","journal-title":"Lancet"},{"key":"84_CR31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0895-7061(99)00037-0","volume":"12","author":"JJ Nawarskas","year":"1999","unstructured":"Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA: Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999, 12(8 Pt 1): 784\u2013789.","journal-title":"Am J Hypertens"},{"key":"84_CR32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S1071-9164(99)90037-4","volume":"5","author":"B Pitt","year":"1999","unstructured":"Pitt B, Poole-Wilson P, Segal R, et al.: Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study (ELITE II). J Card Fail 1999, 5: 146\u2013154.","journal-title":"J Card Fail"},{"key":"84_CR33","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J, for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002, 360: 752\u2013760.","journal-title":"Lancet"},{"key":"84_CR34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0735-1097(99)00537-9","volume":"35","author":"TJ Anderson","year":"2000","unstructured":"Anderson TJ, Elstein E, Haber H, Charbonneau F: Comparative study of ACE inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000, 35: 60\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"84_CR35","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345: 1667\u20131675.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-003-0084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-003-0084-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-003-0084-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:25Z","timestamp":1559432125000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-003-0084-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["84"],"URL":"https:\/\/doi.org\/10.1007\/s11883-003-0084-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}